CClinicalTrials.gg
Sign In
RecruitingNCT02282748Updated Feb 18, 2020

Swiss Longitudinal Cohort

An observational study in Cardiovascular Risk Factors, sponsored by Hypertension Excellence Centre Lucerne. Recruiting at 3 sites in Switzerland. Open to participants aged 6 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-18.

Sponsored by Hypertension Excellence Centre Lucerne · Observational

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 1 month ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
6 Years and older
Sex
All
01

Study summary

The planned research project is a prospective population-based cohort study, similar to the well-known Framingham study in the United States. So far, there is no similar research project in Switzerland.

It is planned to examine of three Swiss municipalities. Recruitment in a first Swiss municipality (Lostallo/Cama GR) started 2014 and ended in 2019. Overall, 496 participants were recruited in this municipality. The five-year follow-up in this municipality started in 2019. It is planned to start recruitment in a second Swiss municipality (Uznach SG) in 2020.

The examinations embrace a broad spectrum of measurements (for details the investigators refer to the published study protocol).

02

Conditions studied

  • Cardiovascular Risk Factors
03

In context

Lead sponsor

This is the only study on the registry with Hypertension Excellence Centre Lucerne as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Population of four Swiss municipalities

Inclusion criteria

  • Resident of Cama GR, Lostallo GR, or Uznach SG
  • Age ≥6 years (no upper age limit), for voluntary blood sample ≥18 years
  • Willing to participate in long-term study
  • Written informed consent (in participants ≥6 years and \<18 years signed by parents)

Exclusion criteria

Exclusion Criteria:

  • No exclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No

Interventions

  • OtherNo intervention
06

What researchers measure

Primary outcomes

  1. Mortality

    Time frame: 10 years

Secondary outcomes

  1. Cardiovascular events

    Cardiovascular events (i.e. stroke, myocardial infarction) will be assessed using questionnaires and case records.

    Time frame: 10 years

  2. Heart function

    Heart function will be assessed using questionnaires for symptoms, clinical examination and measurement of electromechanical activation time.

    Time frame: 10 years

  3. Cognitive function

    Cognitive function will be assessed using validated instruments.

    Time frame: 10 years

  4. Kidney function

    Kidney function will be assessed using laboratory measurements.

    Time frame: 10 years

  5. Autonomy

    Autonomy wil be assessed using validated instruments.

    Time frame: 10 years

  6. Nursing home admission

    Nursing home admissions will be assessed using standardized questions.

    Time frame: 10 years

Other outcomes

  1. Changes in cardiovascular risk factors

    Cardiovascular risk factors will be assessed using validated measurements.

    Time frame: 10 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Publications

  • Pusterla L, Radovanovic D, Muggli F, Erne P, Schoenenberger AW, Schoenenberger-Berzins R, Parati G, Suter P, Lava SAG, Gallino A, Bianchetti MG. Impact of Cardiovascular Risk Factors on Arterial Stiffness in a Countryside Area of Switzerland: Insights from the Swiss Longitudinal Cohort Study. Cardiol Ther. 2022 Dec;11(4):545-557. doi: 10.1007/s40119-022-00280-8. Epub 2022 Sep 24. PubMed 36152116 ↗
  • Schoenenberger AW, Radovanovic D, Muggli F, Suter PM, Schoenenberger-Berzins R, Parati G, Bianchetti MG, Gallino A, Erne P. Prevalence of ideal cardiovascular health in a community-based population - results from the Swiss Longitudinal Cohort Study (SWICOS). Swiss Med Wkly. 2021 Sep 28;151:w30040. doi: 10.4414/smw.2021.w30040. eCollection 2021 Sep 27. PubMed 34581550 ↗
  • Schoenenberger AW, Muggli F, Parati G, Gallino A, Ehret G, Suter PM, Schoenenberger-Berzins R, Resink TJ, Erne P. Protocol of the Swiss Longitudinal Cohort Study (SWICOS) in rural Switzerland. BMJ Open. 2016 Nov 28;6(11):e013280. doi: 10.1136/bmjopen-2016-013280. PubMed 27895066 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 18, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02282748
Lead sponsor
Hypertension Excellence Centre Lucerne
Responsible party
Sponsor
First posted
Nov 4, 2014
Start date
Oct 2014
Primary completion
Sep 2024 (estimated)
Completion
Sep 2034 (estimated)
Last update
Feb 18, 2020

Study contacts

Paul Erne, MD
Contact
paul.erne@erne-net.ch
Andreas W Schoenenberger, MD
Contact
Andreas.Schoenenberger@insel.ch
Paul Erne, MD
study chair · Hypertension Excellence Centre Lucerne
Andreas W Schoenenberger, MD
principal investigator · University Department of Geriatrics, University of Bern
Paolo Suter, MD
principal investigator · University of Zurich
Franco Muggli, MD
principal investigator · Swiss Society of Hypertension
Renate Schoenenberger, MD
principal investigator · Hypertension Excellence Centre Lucerne
Pierre-Alexandre Krayenbühl, MD
principal investigator · Linth Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion